Targeting a specific protein in acute myeloid leukemia with a new treatment approach
Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-2
This study is testing a new treatment for acute myeloid leukemia (AML) that uses a special antibody to target cancer cells, aiming to offer a safer and more effective option for patients who don't have many choices left.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11162010 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for acute myeloid leukemia (AML) by using a specialized antibody that targets the active form of a protein called integrin beta-2. The approach involves creating a radioimmunotherapy that combines this antibody with a radioactive substance to selectively attack cancer cells. By utilizing advanced proteomic technology, the researchers aim to improve the safety and effectiveness of the treatment compared to existing therapies. This innovative strategy could provide a new option for patients who have limited treatment choices.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia who have not responded well to current therapies.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for patients with acute myeloid leukemia.
How similar studies have performed: Similar approaches using radioimmunotherapy have shown success in treating other cancers, indicating potential for this novel strategy in AML.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Wiita, Arun P. — University of California, San Francisco
- Study coordinator: Wiita, Arun P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.